Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open-label trial.

Sanmarti R, Veale DJ, Martin-Mola E, Escudero-Contreras A, González C, Ercole L, Alonso R, Fonseca JE; ToSpace Study group.

Arthritis Rheumatol. 2019 Apr 5. doi: 10.1002/art.40905. [Epub ahead of print]

PMID:
31087542
2.

Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis.

García-Moreno C, Gómara MJ, Bleda MJ, Sanmartí R, Haro I.

PLoS One. 2019 May 2;14(5):e0215927. doi: 10.1371/journal.pone.0215927. eCollection 2019.

3.

Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.

Bastida C, Soy D, Ruiz-Esquide V, Sanmartí R, Huitema ADR.

Br J Clin Pharmacol. 2019 Apr 8. doi: 10.1111/bcp.13954. [Epub ahead of print]

PMID:
30958574
4.

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study.

Moreno M, Gratacós J, Torrente-Segarra V, Sanmarti R, Morlà R, Pontes C, Llop M, Juanola X; REMINEA study Group.

Arthritis Res Ther. 2019 Apr 5;21(1):88. doi: 10.1186/s13075-019-1873-3.

5.

Hyperlipoprotein(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project.

García-Gómez C, Martín-Martínez MA, Fernández-Carballido C, Castañeda S, González-Juanatey C, Sanchez-Alonso F, González-Fernández MJ, Sanmartí R, García-Vadillo JA, Fernández-Gutiérrez B, García-Arias M, Manero FJ, Senabre JM, Rueda-Cid A, Ros-Expósito S, Pina-Salvador JM, Erra-Durán A, Möller-Parera I, Llorca J, González-Gay MA; CARMA Project Collaborative Group.

Clin Exp Rheumatol. 2019 Feb 15. [Epub ahead of print]

PMID:
30789151
6.

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Pethö-Schramm A.

Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393.

7.

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.

Gratacós J, Pontes C, Juanola X, Sanz J, Torres F, Avendaño C, Vallano A, Calvo G, de Miguel E, Sanmartí R; REDES-TNF investigators.

Arthritis Res Ther. 2019 Jan 8;21(1):11. doi: 10.1186/s13075-018-1772-z.

8.

Ultrasound findings in palindromic rheumatism.

Sanmarti R, Ramírez J, Castellanos-Moreira R, Cabrera-Villalba SR, Ruiz-Esquide V, Salvador G.

Ann Rheum Dis. 2018 Dec 14. pii: annrheumdis-2018-214832. doi: 10.1136/annrheumdis-2018-214832. [Epub ahead of print] No abstract available.

PMID:
30552178
9.

Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.

Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Fernández Nebro A, Muñoz-Fernández S, González CM, Roig D, Zarco P, Erra A, Rodríguez J, Castañeda S, Rubio E, Salvador G, Díaz-Torné C, Blanco R, Willisch Domínguez A, Mosquera JA, Vela P, Sánchez-Fernández SA, Corominas H, Ramírez J, de la Cueva P, Fonseca E, Fernández E, Puig L, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno D, Vanaclocha F, Herrera E, Blanco F, Fernández-Gutiérrez B, González A, Pérez-García C, Alperi-López M, Olivé Marques A, Martínez-Taboada V, González-Álvaro I, Sanmartí R, Tomás Roura C, García-Montero AC, Bonàs-Guarch S, Mercader JM, Torrents D, Codó L, Gelpí JL, López-Corbeto M, Pluma A, López-Lasanta M, Tortosa R, Palau N, Absher D, Myers R, Marsal S, Julià A.

Ann Rheum Dis. 2019 Mar;78(3). pii: e214158. doi: 10.1136/annrheumdis-2018-214158. Epub 2018 Dec 14.

PMID:
30552173
10.

Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.

Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.

Arthritis Res Ther. 2018 Dec 13;20(1):275. doi: 10.1186/s13075-018-1764-z.

11.

Practical Aspects of Biological Throughput Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis.

Rosas J, Martín-López M, Otón T, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Carmona L.

Reumatol Clin. 2018 Oct 29. pii: S1699-258X(18)30220-1. doi: 10.1016/j.reuma.2018.09.006. [Epub ahead of print] English, Spanish.

12.

Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review.

Calvo Alén J, Pérez T, Romero Yuste S, Ferraz-Amaro I, Alegre Sancho JJ, Pinto Tasende JA, Maceiras Pan F, Quevedo JC, Hernández-Hernández MV, Hidalgo Calleja C, San Martín Álvarez A, Sánchez MIT, Sanmartí R.

Reumatol Clin. 2018 Sep 18. pii: S1699-258X(18)30175-X. doi: 10.1016/j.reuma.2018.07.016. [Epub ahead of print] English, Spanish.

13.

Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure.

Blanco FJ, Rubio-Romero E, Sanmartí R, Díaz-Torné C, Talavera P, Dunkel J, Naredo E; SONAR Study Team.

Reumatol Clin. 2018 Sep 17. pii: S1699-258X(18)30168-2. doi: 10.1016/j.reuma.2018.07.009. [Epub ahead of print] English, Spanish.

14.

Assessing Treatment Tolerability for Rheumatoid Arthritis. Validation and Practical Applications of the 'TOL-AR-18 Questionnaire'.

Corominas H, Espadaler L, Gómez A, Ros I, Urruticoechea A, Sarmiento M, Sanmartí R.

Reumatol Clin. 2018 Sep 5. pii: S1699-258X(18)30123-2. doi: 10.1016/j.reuma.2018.06.005. [Epub ahead of print] English, Spanish.

15.

Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis.

Tornero Molina J, Balsa Criado A, Blanco García F, Blanco Alonso R, Bustabad S, Calvo Alen J, Corominas H, Fernández Nebro A, Román Ivorra JA, Sanmartí R.

Reumatol Clin. 2018 Aug 8. pii: S1699-258X(18)30136-0. doi: 10.1016/j.reuma.2018.07.004. [Epub ahead of print] English, Spanish.

16.

Efficacy and Safety of Glucocorticoids in Rheumatoid Arthritis: Systematic Literature Review.

Sanmartí R, Tornero J, Narváez J, Muñoz A, Garmendia E, Ortiz AM, Abad MA, Moya P, Mateo ML, Reina D, Salvatierra-Ossorio J, Rodriguez S, Palmou-Fontana N, Ruibal-Escribano A, Calvo-Alén J.

Reumatol Clin. 2018 Jul 26. pii: S1699-258X(18)30125-6. doi: 10.1016/j.reuma.2018.06.007. [Epub ahead of print] English, Spanish.

17.

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A.

Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. No abstract available.

18.

Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review.

Martín-López M, Carmona L, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Rosas J.

Rheumatol Int. 2018 Jun;38(6):975-983. doi: 10.1007/s00296-018-4022-4. Epub 2018 Apr 3.

PMID:
29616303
19.

Tocilizumab in the treatment of adult rheumatoid arthritis.

Sanmartí R, Ruiz-Esquide V, Bastida C, Soy D.

Immunotherapy. 2018 Mar 1;10(6):447-464. doi: 10.2217/imt-2017-0173. Epub 2018 Mar 2.

PMID:
29495891
20.

Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.

Balsa A, Sanmarti R, Rosas J, Martin V, Cabez A, Gómez S, Montoro M.

Rheumatology (Oxford). 2018 Apr 1;57(4):688-693. doi: 10.1093/rheumatology/kex474.

PMID:
29365183
21.

Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.

Bastida C, Ruiz-Esquide V, Pascal M, de Vries Schultink AHM, Yagüe J, Sanmartí R, Huitema ADR, Soy D.

Br J Clin Pharmacol. 2018 Apr;84(4):716-725. doi: 10.1111/bcp.13500. Epub 2018 Feb 7.

22.

REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.

González-Álvaro I, Blasco AJ, Lázaro P, Sánchez-Piedra C, Almodovar R, Bachiller-Corral J, Balsa A, Caliz R, Candelas G, Fernández-Carballido C, García-Aparicio A, García-Magallón B, García-Vicuña R, Gómez-Centeno A, Ortiz AM, Sanmartí R, Sanz J, Tejera B.

Heliyon. 2017 Nov 14;3(11):e00452. doi: 10.1016/j.heliyon.2017.e00452. eCollection 2017 Nov.

23.

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A.

Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum in: Rheumatology (Oxford). 2018 Jun 1;57(6):1129.

24.

The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.

Diaz-Torne C, Ortiz MDA, Moya P, Hernandez MV, Reina D, Castellvi I, De Agustin JJ, Fuente D, Corominas H, Sanmarti R, Zamora C, Cantó E, Vidal S.

Semin Arthritis Rheum. 2018 Jun;47(6):757-764. doi: 10.1016/j.semarthrit.2017.10.022. Epub 2017 Nov 20.

PMID:
29157669
25.

Sustained response to rituximab in a TNFi-induced ANCA-vasculitis developed in a patient with rheumatoid arthritis.

Florez H, Morlà R, Castellanos-Moreira R, Sanmartí R.

Semin Arthritis Rheum. 2018 Feb;47(4):e15-e16. doi: 10.1016/j.semarthrit.2017.07.006. Epub 2017 Jul 13. No abstract available.

PMID:
29150206
26.

Genetic variation associated with cardiovascular risk in autoimmune diseases.

Perrotti PP, Aterido A, Fernández-Nebro A, Cañete JD, Ferrándiz C, Tornero J, Gisbert JP, Domènech E, Fernández-Gutiérrez B, Gomollón F, García-Planella E, Fernández E, Sanmartí R, Gratacós J, Martínez-Taboada VM, Rodríguez-Rodríguez L, Palau N, Tortosa R, Corbeto ML, Lasanta ML, Marsal S, Julià A; IMID Consortium.

PLoS One. 2017 Oct 5;12(10):e0185889. doi: 10.1371/journal.pone.0185889. eCollection 2017.

27.

Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays.

Gómara MJ, Rodríguez J, Bleda MJ, Salvador JP, Sanmartí R, Haro I.

Clin Chem Lab Med. 2018 Jan 26;56(2):285-293. doi: 10.1515/cclm-2017-0264.

PMID:
28850543
28.

A composite indicator to assess the quality of care in the management of patients with rheumatoid arthritis in outpatient rheumatology clinics.

Martín-Martínez MA, Andreu-Sanchez JL, Sanchez-Alonso F, Corominas H, Perez-Venegas JJ, Roman-Ivorra JA, Alperi M, Blanco-Alonso R, Caliz R, Chamizo-Carmona E, Graña-Gil J, Hernández B, Marras C, Mazzucchelli R, Medina Luezas JA, Naranjo-Hernández A, Ortiz A, Roselló R, Sanchez-Nievas G, Sanmartí R, Vela-Casasempere P; en representación del Comité Científico del trabajo Indicador Compuesto para evaluar la calidad asistencial en el manejo de los pacientes con artritis reumatoide en las consultas externas de Reumatología.

Reumatol Clin. 2019 May - Jun;15(3):156-164. doi: 10.1016/j.reuma.2017.06.017. Epub 2017 Aug 6. English, Spanish.

29.

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study.

Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, Ruiz-Esquide V, Corrales A, Narváez J, Rey-Rey J, Rodríguez-Lozano C, Ojeda S, Muñoz-Fernández S, Nolla JM, García-Torrón J, Gamero F, García-Vicuña R, Hernández-Cruz B, Campos J, Rosas J, García-Llorente JF, Gómez-Centeno A, Cáliz R, Sanmartí R, Bermúdez A, Abasolo-Alcázar L, Fernández-Nebro A, Rodríguez-Rodríguez L, Marras C, González-Gay MÁ, Hmamouchi I, Martín-Mola E.

Reumatol Clin. 2019 Mar - Apr;15(2):102-108. doi: 10.1016/j.reuma.2017.06.002. Epub 2017 Jul 12. English, Spanish.

30.

Musculoskeletal Involvement in Hereditary Hemochromatosis.

Castellanos-Moreira R, Rodríguez-García SC, Florez H, Inciarte-Mundo J, Sanmarti R.

J Clin Rheumatol. 2017 Aug;23(5):291. doi: 10.1097/RHU.0000000000000544. No abstract available.

PMID:
28700532
31.

Safety profile of biological therapies for treating rheumatoid arthritis.

Cañete JD, Hernández MV, Sanmartí R.

Expert Opin Biol Ther. 2017 Sep;17(9):1089-1103. doi: 10.1080/14712598.2017.1346078. Epub 2017 Jul 17. Review.

PMID:
28657381
32.

Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.

Cabrera-Villalba S, Gomara MJ, Cañete JD, Ramírez J, Salvador G, Ruiz-Esquide V, Hernández MV, Inciarte-Mundo J, Haro I, Sanmartí R.

Arthritis Res Ther. 2017 Jun 15;19(1):141. doi: 10.1186/s13075-017-1329-6.

33.

Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.

Ramírez J, Narváez JA, Ruiz-Esquide V, Hernández-Gañán J, Cuervo A, Inciarte-Mundo J, Hernández MV, Sampayo-Cordero M, Pablos JL, Sanmartí R, Cañete JD.

Semin Arthritis Rheum. 2017 Dec;47(3):303-309. doi: 10.1016/j.semarthrit.2017.04.007. Epub 2017 May 1.

PMID:
28549731
34.

Recommendations for the use of parenteral methotrexate in rheumatic diseases.

Tornero Molina J, Calvo Alen J, Ballina J, Belmonte MÁ, Blanco FJ, Caracuel MÁ, Carbonell J, Corominas H, Chamizo E, Hidalgo C, Ivorra JR, Marenco JL, Moreno Muelas JV, Muñoz-Fernández S, Nolla JM, Pérez T, Sanmarti R, Trenor P, Urrego C, Vidal J, Rosas Gomez de Salazar J.

Reumatol Clin. 2018 May - Jun;14(3):142-149. doi: 10.1016/j.reuma.2016.12.001. Epub 2017 Jan 9. English, Spanish.

35.

Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?

Bastida C, Ruíz V, Pascal M, Yagüe J, Sanmartí R, Soy D.

Br J Clin Pharmacol. 2017 May;83(5):962-975. doi: 10.1111/bcp.13192. Epub 2017 Jan 18. Review.

36.

Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.

Ramírez J, Inciarte-Mundo J, Cuervo A, Ruiz-Esquide V, Hernández MV, Sanmartí R, Cañete JD.

Clin Exp Rheumatol. 2017 Jan-Feb;35(1):74-79. Epub 2016 Oct 7.

PMID:
27749227
37.

Reply.

Inciarte-Mundo J, Sanmarti R.

Arthritis Care Res (Hoboken). 2017 Apr;69(4):606-607. doi: 10.1002/acr.23125. Epub 2017 Mar 3. No abstract available.

38.

Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.

Inciarte-Mundo J, Ramirez J, Hernández MV, Ruiz-Esquide V, Cuervo A, Cabrera-Villalba SR, Pascal M, Yagüe J, Cañete JD, Sanmarti R.

Arthritis Res Ther. 2016 Jul 8;18(1):160. doi: 10.1186/s13075-016-1032-z.

39.

Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Martin-Mola E, Balsa A, García-Vicuna R, Gómez-Reino J, González-Gay MA, Sanmartí R, Loza E.

Rheumatol Int. 2016 Aug;36(8):1043-63. doi: 10.1007/s00296-016-3506-3. Epub 2016 Jun 6. Review.

PMID:
27271502
40.

Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission.

Ramírez J, Celis R, Usategui A, Ruiz-Esquide V, Faré R, Cuervo A, Sanmartí R, Pablos JL, Cañete JD.

Arthritis Res Ther. 2016 Mar 31;18:74. doi: 10.1186/s13075-016-0970-9.

41.

Variability in Rheumatology day care hospitals in Spain: VALORA study.

Hernández Miguel MV, Martín Martínez MA, Corominas H, Sanchez-Piedra C, Sanmartí R, Fernandez Martinez C, García-Vicuña R; en representación del Comité Científico del proyecto VALORA.

Reumatol Clin. 2017 Jan - Feb;13(1):10-16. doi: 10.1016/j.reuma.2016.01.007. Epub 2016 Mar 9. English, Spanish.

42.

The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.

Hernández MV, Sanmartí R, Cañete JD.

Expert Opin Drug Saf. 2016 May;15(5):613-24. doi: 10.1517/14740338.2016.1160054. Epub 2016 Mar 21. Review.

PMID:
26927029
43.

Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.

Inciarte-Mundo J, Victoria Hernández M, Ruiz-Esquide V, Raquel Cabrera-Villalba S, Ramirez J, Cuervo A, Pascal M, Yagüe J, Cañete JD, Sanmarti R.

Arthritis Care Res (Hoboken). 2016 Jul;68(7):899-906. doi: 10.1002/acr.22795. Erratum in: Arthritis Care Res (Hoboken). 2017 Jan;69(1):155.

44.

Diagnostic and therapeutic delay of rheumatoid arthritis and its relationship with health care devices in Catalonia. The AUDIT study.

Corominas H, Narváez J, Díaz-Torné C, Salvador G, Gomez-Caballero ME, de la Fuente D, Campoy E, Roig-Vilaseca D, Clavaguera T, Morlà R, Torrente-Segarra V, Arasa X, Gomez-Puerta JA, Möller I, Alegre C, Graell E, Ponce A, Lisbona MP, Pérez-Garcia C, Fíguls R, Sirvent E, Poca V, Sanmartí R.

Reumatol Clin. 2016 May-Jun;12(3):146-50. doi: 10.1016/j.reuma.2015.08.002. Epub 2015 Sep 8. English, Spanish.

45.

Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial.

Pontes C, Gratacós J, Torres F, Avendaño C, Sanz J, Vallano A, Juanola X, de Miguel E, Sanmartí R, Calvo G.

Trials. 2015 Aug 20;16:370. doi: 10.1186/s13063-015-0828-5.

46.

Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.

Narváez J, Magallares B, Díaz Torné C, Hernández MV, Reina D, Corominas H, Sanmartí R, LLobet JM, Rodriguez de la Serna A, Nolla JM.

Semin Arthritis Rheum. 2016 Feb;45(4):386-90. doi: 10.1016/j.semarthrit.2015.07.001. Epub 2015 Jul 6.

PMID:
26254548
47.

Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.

Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, Cañete JD, Cabrera-Villalba SR, Ramirez J, Yagüe J, Sanmarti R.

Rheumatology (Oxford). 2015 Dec;54(12):2239-43. doi: 10.1093/rheumatology/kev251. Epub 2015 Aug 4.

PMID:
26242859
48.

Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis.

Cañete JD, Celis R, Yeremenko N, Sanmartí R, van Duivenvoorde L, Ramírez J, Blijdorp I, García-Herrero CM, Pablos JL, Baeten DL.

Arthritis Res Ther. 2015 Jul 9;17:173. doi: 10.1186/s13075-015-0688-0.

49.

2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.

Sanmartí R, García-Rodríguez S, Álvaro-Gracia JM, Andreu JL, Balsa A, Cáliz R, Fernández-Nebro A, Ferraz-Amaro I, Gómez-Reino JJ, González-Álvaro I, Martín-Mola E, Martínez-Taboada VM, Ortiz AM, Tornero J, Marsal S, Moreno-Muelas JV.

Reumatol Clin. 2015 Sep-Oct;11(5):279-94. doi: 10.1016/j.reuma.2015.05.001. Epub 2015 Jun 6. English, Spanish.

50.

IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients.

Ortiz MA, Diaz-Torné C, Hernández MV, Reina D, de la Fuente D, Castellví I, Moya P, Ruiz JM, Corominas H, Zamora C, Cantó E, Sanmartí R, Juarez C, Vidal S.

Clin Immunol. 2015 Jun;158(2):174-82. doi: 10.1016/j.clim.2015.03.025. Epub 2015 Apr 3.

PMID:
25847223

Supplemental Content

Loading ...
Support Center